Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by DNE Capital, with participation from Yuanbio Venture Capital, its angel financing investor. The funds will be used to advance the industrialization of the fourth-generation A type botox product and the application of Zinc Finger Proteins (ZFPs) drug delivery technology in recombinant protein drugs.
Market Potential and Technology Focus
Botulinum toxin, a market worth hundreds of millions of renminbi in the drug therapy and medical aesthetics fields, has garnered over 20 indication approvals worldwide. Asiflyer Bio’s focus on advancing this technology and product line aligns with the growing demand and potential in both therapeutic and aesthetic applications.
About Asiflyer Bio
Asiflyer Bio is dedicated to developing innovative recombinant protein drugs, leveraging cutting-edge technologies such as ZFPs to enhance drug delivery and efficacy. This financing round will support the company’s efforts to bring its advanced products to market, expanding its presence in the global biopharmaceutical industry.-Fineline Info & Tech
